Cardiff Oncology, Inc. Announces Executive Changes
December 21, 2020 at 04:18 pm
Share
On December 21, 2020, Cardiff Oncology, Inc. (the “Company”) announced that Thomas H. Adams, Ph.D., Executive Chairman and Chairman of the Company, stepped down from his current role, effective December 15, 2020, and will continue as a director of the Company. In addition, the Company announced that Rodney Markin, M.D. was appointed as Chairman of the Board, effective December 15, 2020.
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
CARDIFF ONCOLOGY, INC. 
